Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Subscribe To Our Newsletter & Stay Updated
